U01.11.048 Polymyositis & Dermatomyositis

Learning Objectives

Differentiate Polymyositis (PM) from Dermatomyositis (DM) by their unique histopathological triggers (CD8+ vs. CD4+) and clinical skin findings. Identify high-yield autoantibodies such as Anti-Jo-1 and Anti-Mi-2, and recognize the critical association between Dermatomyositis and occult malignancy.


1. Inflammatory Myopathies Overview

Both conditions present with progressive, symmetric proximal muscle weakness (e.g., difficulty climbing stairs or combing hair). While the weakness is similar, the underlying immunology and cutaneous involvement differ significantly.

Feature Polymyositis (PM) Dermatomyositis (DM)
Inflammation Endomysial (within the fascicle). Perimysial (around the fascicle).
Cell Type CD8+ T cells. CD4+ T cells and B cells.
Skin Findings None. Gottron papules, Heliotrope rash, Shawl sign.
Malignancy Lower risk. Increased risk of occult cancer.

2. Cutaneous Hallmarks of Dermatomyositis

Dermatomyositis is often identified by “vignette-classic” skin lesions that accompany the muscle weakness.

  • Gottron Papules: Red-to-violet papules found over the bony prominences (MCP, PIP, DIP joints).
  • Heliotrope Rash: Violaceous (purple) edema/rash of the upper eyelids.
  • Shawl and V-Sign: Erythema on the upper back/shoulders (Shawl) or upper chest (V-sign).
  • Mechanic’s Hands: Cracked, dirty-appearing skin on the lateral and palmar aspects of the fingers.

Activity: Comparison Challenge

Antibody Target / Association
Anti-Jo-1 Histidyl-tRNA synthetase (associated with interstitial lung disease).
Anti-SRP Signal Recognition Particle.
Anti-Mi-2 Helicase (highly specific for Dermatomyositis).
ANA / CK Nonspecific; Elevated CK is a hallmark of muscle damage.

High-Yield Mnemonics:

  • Cell Types: Polymyositis = CD8+ (Peights are 8). Dermatomyositis = CD4+ (D is 4th letter).
  • Location: Dermatomyositis is Distant from the muscle (Perimysial). Polymyositis is Penetrating the muscle (Endomysial).
  • Jo-1: Think “Joe’s Lungs” for the association with Interstitial Lung Disease.

Activity: